

A Mini-Review on Breast Cancer-Risk factors, Treatment and Prevention

Guthi Gouthami ¹, M Renuka ² and D Sangeetha Rani ³
^{1,2,3} Department of Botany, University College of science, Saifabad,
Osmania University, Hyderabad, Telangana, India

Micro abstract

Now day's life cancer deaths are increasing tremendously, especially breast cancer deaths in women increasing rapidly all over the world. Due to change in life style and several other factors breast cancer easily develops in women. The current review article describes the various risk factors associated with breast cancer and also describes the different modes of treatment, preventive factors.

Abstract

Cancer is a result of uncontrolled growth of abnormal cells in the body caused by genetic and environmental factors. Modern lifestyle changes, food choices, genetic vulnerability, family history, oestrogen exposure, age, late night working, hazardous chemical exposure, obesity in the post-menopausal phase, exposure to high doses of radiation are some of the main factors which increases the risk of breast cancer. It is the frequently diagnosed and leading cause of cancer deaths in women in worldwide. This article presents a systematic review of the Breast Cancer literature describing the risk factors, treatment methods and preventive steps of breast cancer. Breastcancertreatment, and prevention are prominent issues in publichealth and medical practice. The current approach to this disease involves early detection and treatment. The available literature in this review aims to bring the awareness of healthcare professionals and clinical doctors to improve the quality of treatment and suggesting breast cancer patients to follow the preventive steps.

Key words : Breast cancer, ductal carcinoma in situ, lobular carcinomain situ, breast cancer treatment, Risk factors, Treatment and Prevention.

Introduction

Breast cancer is the most common cancer of adult females in all over the world (140 of 180 countries) [1], and after lung cancer, it is the second leading cause of cancer death [2]. One in eight women in the UK, USA and one in twenty in India develop the disease in their lifetimes. The age-standardized incidence rate (ASR) of breast cancer is 39.0 per 100,000, which is higher than that of cervical cancer (cervical cancer ASR=15.2 per 100,000)[3, 4, 38, 39]. In 2015, an estimated 60,290 in situ breast cancer cases and 2, 31,240 invasive breast cancer cases were diagnosed in United States. And approximately 40,290 women expected to die from breast cancer [93]. Between 2008-2012 the breast cancer incidence increased by 25%, while death rate due to breast cancer increased by 14% [36]. In US, it is estimated that there are 3.1 million breast cancer survivors presently [37]. It is estimated that 70% of breast cancers are hormone receptor positive, and genetic mutations like BRCA 1 and BRCA 2 genes leads to breast cancer development with 60-80% life time risk [40-42]. It is more common in the Western countries than South America, Asia, and Africa. Several aetiological factors have been implicated in its pathogenesis.

The causative factors include age, genetics, family history, diet, alcohol, obesity, life style, physical inactivity, chemical exposure, previous benign disease, mammographic density and exposure to high dose of ionizing radiation. Each factor has its unique role in the pathogenesis of breast cancer and difficult to predict that the single factor has higher risk of causing breast cancer. In most of the areas this cancer is seen in one fourth of all female cancers, which concludes that this cancer is most common in western countries and fast grown up cancer in Asian countries [2, 5, and 37].

Breast cancer is a tumour that starts from cells of the breast tissue, cells of the ducts and lobules where breast cancer mostly begins. Breast cancer are of two types benign and malignant, the former are not life-threatening, can usually remove by surgery, they do not invade adjacent tissue or do not spread to the other parts of the body. Malignant breast tumours are cancerous and can invade adjacent tissue or metastasize to other part of the body through lymphatic system. If breast cancer cells enter into the lymphatic system then there is a higher probability that the tumour enter into the blood stream and metastasizes to other part of the body [92].

Risk factors

Genetic risk factors: The mutations in BRCA1 and BRCA2 increases the risk of breast cancer and account for 5%-10% of all female breast cancers. [70, 71] the average risk for BRCA1 and BRCA2 mutation carriers is estimated to be between 57%-65% and 45%-55%, respectively [72-74].

Family history: Breast cancer risk is higher in closed blood relatives (mother, sister, daughter, father, brother, or son). Risk increases with increasing first degree relatives. [94]

Personal history of breast cancer: A woman with cancer in one breast has a higher chance of getting breast cancer in another breast. The risk is high at the age of 40, and decreases significantly with increasing age at diagnosis of primary breast cancer [77-79].

Race

Black women have higher chances of getting breast cancer before age 45. Generally white women have higher chances of getting breast cancer than African-American women, Asian women due to changes in their lifestyle. African-American women are more likely to die of breast cancer. [95-96]

Dense breast tissue: Dense breast tissue means there is more gland tissue and less fatty tissue. Women with denser breast tissue have a higher risk of breast cancer [97]. Breast glandular and connective tissue increases the risk of breast cancer, density may be reduced by pregnancy and menopause. Breast density is lower in heavy weight women due to higher production of fatty tissue [98]

Benign breast problems: Benign breast disease is fibrocystic disease with changes in breast tissue, it have no clinical symptoms, and it can be removed by biopsy. Benign breast disease is classified in to non-proliferative including fibro adenoma, adenosis, cysts and fibrosis, proliferative without atypia and proliferative with atypia. Women with benign breast disease have higher risk of breast cancer. [99]

Lobular carcinoma in situ: In this condition, cells that look like cancer cells are in the lobules and cannot spread to other parts of the body. There are no clinical symptoms observed and cannot be detected in mammography. Women with LCIS have higher risk of getting invasive breast cancer within 5- 10 years. [84, 85]

Menstrual periods: Epidemiological studies of breast cancer have shown that Women who have periods before the age of 12 and after the menopause age of 55 are slightly increased the risk (10% to 20%) of breast cancer. [80, 81-83]

Breast radiation early in life: Women exposed to ionizing radiation for medical purposes for diagnosis and some working women exposes to highly lethal radiation at work place which influence the risk of breast cancer. Women exposes to radiation before the age of 20 have higher chances of getting breast cancer. [100, 101]

Treatment with DES: Diethylstilboestrol (DES), a potent pharmaceutical estrogen used by millions of pregnant women between 1940 and the 1970s to prevent miscarriages. Studies eventually revealed that *in utero* DES exposure of both male and female offspring increased neoplastic lesions of the reproductive tract and the incidence of benign reproductive problems. Women who were exposed *in utero* to DES had a significantly increased risk of breast cancer. Their mothers also experienced an increased risk of breast

cancer [11, 12]. Importantly, the highest risks were correlated with the highest cumulative doses of DES during pregnancy [13].

Not having children or having them later in life: Women who had first child at the age of 30, who do not had children up to 30 and 35 years have slightly higher risk of breast cancer. Being pregnant many times or pregnancy at young age also reduces the risk of breast cancer [93].

Birth control pills: women using birth control pills or an injectable form of birth control called *depot-medroxyprogesteroneacetate* (DMPA or Depo-Provera®) have a slightly greater risk of breast cancer than women who have never used them. The risk goes back to the normal when women stop using birth control pills [93].

Hormone therapy after menopause: A pooled analysis in 1997 suggest that taking oestrogen alone after the menopause increase the risk of 14% of getting breast cancer. Women who had hormone replacement therapy up to 5 years had 35% of higher risk than non-users [102].

A women's risk increases within a year and goes up for each year if she continues the combination hormones.

Not breastfeeding:

Breast feeding for duration more than one year lowers the risk of getting breast cancer and protective of breast cancer. Breast feeding less than 10 months have a little high risk of breast cancer. [24]

Alcohol: The intake of alcohol is directly linked to the risk of getting breast cancer. Even one drink per a day can increase risk.

Alcohol (especially beer) consumed more than 10 g/day especially among postmenopausal women is a risk factor for developing invasive breast cancer. [43,44]

Being overweight or obese: Women with large weight before and after the menopause has a higher chances of getting breast cancer [75]. Risk is about 1.5 times higher in overweight women than in non-obese women [76]. Due to heavy weight, fat deposition increases in the body and the fat tissue is the largest source of oestrogen in post-menopausal women.

Tobacco smoke: Studies linking smoking to breast cancer have had mixed results, epidemiological studies have reported that smoking may increase the risk of breast cancer. The increased risk seems to be higher in certain groups, such as women who started smoking before they had their first child and continues for longer durations. [86-89]

Diet rich in fats

Diets rich in fats increases the incidence of breast cancer, diets containing 35-40% of fat in calories have a higher chances of producing breast tumour. Diet containing higher amount of fats are the source of cholesterol which is a precursor for the synthesis of estrogen hormone, exposure of breast to higher amount of estrogen leads to the development of cancer. [1]

Hyper-insulinemia

It has been hypothesised that excessive levels of insulin in blood levels is associated with increased risk of breast cancer, because excessive levels of insulin in circulation would promote cell growth in breast tissues and increase circulating levels of oestrogens, testosterone and insulin-like growth factors. [23]

A metaanalysis including case-control studies and cohort studies says that breast cancer risk for women with diabetes mellitus was 20% higher than for women without diabetes mellitus (RR 1.20, 95% CI: 1.12-1.28). The summary estimates were similar for case-control and cohort studies. [24]

The association between hyperinsulinemia and breast cancer risk represents a public health challenge, due to the high and increasing prevalence of insulin resistance in most developed countries. However, it would also represent a modifiable risk factor that could be controlled by physical activity and weight control.

Obesity Lifestyle

Obesity elevates the risk of breast cancer in post-menopausal women. Breast cancer risk is commonly seen among obese women who don't use hormone replacement therapy, and for each 5 kg of weight gain, breast cancer risk increases by 9%. This fat in adipose tissue is the main source of oestrogens, exposure of higher levels of estrogen increases the risk of breast cancer. [2]

Working women

Women working at night has a 35% higher in risk of getting breast cancer than women who works in day shifts. The women who works at least 3 night shifts per week for more than two years has a higher risk of getting breast cancer than the women who works one to two night shifts per week.

Working at night and sleeping at day time reverse the body's circadian rhythm, which alters the melatonin level, artificial light at night suppress the levels of melatonin, which further affects the hormone levels and leads to the development of breast cancer. Breast cancer patients have low levels of melatonin compared to women without disease. [19-22]

Human Epidermal Growth Factor

The human epidermal growth factor receptor 2 (ErbB2; formerly HER2) gene is part of a family of genes that plays roles in regulating cell growth. Amplification of this gene occurs in a significant proportion of breast, ovarian, and gastric cancers, so that instead of having two gene copies of ErbB2, as would be the case in a normal cell, there are multiple copies, referred to as "ErbB2-positive." As a result, there is far more expression (activity) of the ErbB2 protein on the cell surface, resulting in tumours that are faster growing, more aggressive and less sensitive to therapy. An estimated 20 to 25 percent of breast cancers make these extra copies of the ErbB2 gene.⁶

Treatment

Surgery

Surgery is the most preferred, first line treatment for breast cancer people. The aim of surgery is to remove cancerous tissue in breast and to find out affected lymphatic vessels in armpit area.

Surgery is of two types:

Breast conserving surgery-where the affected cancer tissue is removed along with the little amount of surrounding tissue but healthy breast tissue is not removed.

A mastectomy- where the whole breast is removed, often including some or all lymph nodes in the armpit. Increasingly, although long-term outcomes are very similar for patients who have BCS and mastectomy, patients eligible for BCS are electing mastectomy. Reasons include reluctance to undergo radiation therapy after BCS and fear of recurrence.⁶⁸ Younger women (those under 40 years of age) and patients with larger and/or more aggressive tumours are also more likely to undergo mastectomy. [68, 69]

Axillary (armpit) surgery:

Breast cancer can invade to the adjacent lymphatic vessels in the armpit area. Lymphatic vessels found in armpit area and other areas of the body are part of the immune system. If lymph nodes and lymphatic vessels are affected with the cancer tissue, then surgery to remove the affected area and further follow the radiotherapy, which reduces the recurring of breast cancer back.

Techniques used to detect the cancer in armpit area:

Sentinel node biopsy- one lymph node is removed from armpit area

Axillary node sampling- more than four lymph nodes are removed from armpit area.

Chemotherapy

Chemotherapy is a treatment with one or more anticancer (cytotoxic) drugs to kill the cancer cells. It aims to stop the breast cancer spreading or coming back. It makes less chances of breast cancer to come back in future. Most women having chemotherapy are treated with combination of two different drugs – this is known as multi- drug chemotherapy or combination therapy. Chemotherapy is a systemic treatment, which means it circulates throughout the body. It affects healthy body cells as well as cancer cells – and this is what causes side effects. The dose of given drug is calculated in such a way that it should show higher impact on cancer cells and least impact on normal body cells. Research studies have shown that combination chemotherapy (using more than one drug) is generally more effective than treatment with just one drug. This is because the different drugs act in slightly different ways, so together they have potentially greater impact on cancer cells.

Doxorubicin (Adriamycin) is one of the anthracyclines, an antibiotic and class of chemotherapy that is effective against several types of cancer including breast.

Their mechanisms of action are to inhibit and block DNA and RNA synthesis and create free oxygen radicals that damage the DNA and cell membranes. [45,46]

Radiotherapy

Radiotherapy- treatment with radiation- is given after surgery to remove cancer cells after surgery. Generally radiotherapy is given after surgery for early breast cancer. Radiotherapy is usually given externally with high energy x-rays.

Radiotherapy also affects healthy cells, but they are generally able to recover and repair themselves. Damage to healthy cells can be reduced by giving small doses of radiotherapy regularly. [47] Breast conserving surgery (BCS) is almost always followed by radiation therapy because it has been shown to reduce the risk of breast cancer recurrence by about 50% and the relative risk of breast cancer death by about 20% in most patients [60]. Although there is a higher risk of local recurrence (cancer returning to the breast) with BCS than with mastectomy, clinical trials have confirmed that a woman who chooses BCS and radiation will have the long-term survival. [61-63]

Hormone therapy

Hormones are chemical messengers that are created in endocrine glands which controls the growth and activity of cells in the body. Oestrogen and progesterone are female sexual hormones which are essential for the development and functioning of female reproductive organs and they help to maintain healthy bones and heart. However, they can also encourage the growth of some breast cancers. About 2 to 3% of breast cancers are sensitive to hormones. Hormone therapies block the production of oestrogen and progesterone hormones and stop the hormones from signalling to the breast cancer cells. Hormone therapies are only effective in treating breast cancers that are hormone positive.

Hormone therapies for breast cancer should not be confused with hormone replacement therapy (HRT), which is used to treat the symptoms of menopause. HRT **increases** the levels of hormones in the body, whereas hormone therapies **decrease** hormone levels.

Types of hormone therapy

Two types of hormone therapy that are commonly used are:

- 1) Tamoxifen- For the treatment of women with hormone positive breast cancer. It can be used in women both before and after the menopause
- 2) Aromatase inhibitors, ex: anastrozole (Arimidex), Exemestane (Aromasin), and Letrozole (Femara) - An addition or alternate to tamoxifen for post-menopausal women with hormone positive breast cancer.

Tamoxifen has been commonly used in the treatment of hormone positive early breast cancer for many years. Tamoxifen works by preventing oestrogen from signalling to cancer cells. Most women who are given tamoxifen take it for five years. The usual dose is one 20mg tablet, taken once a day. Treatment of ER+

breast cancer with tamoxifen for at least 5 years has been shown to reduce the rate of recurrence by approximately 40%-50% throughout the first decade, and reduces breast cancer mortality by about one-third throughout the first 15 years.[64] More recently, studies have shown that extended use of tamoxifen (10 years versus 5 years) further reduces the risk of breast cancer recurrence and mortality, so clinical practice guidelines now recommend consideration of adjuvant tamoxifen therapy for 10 years.[65-67]

PREVENTION

Healthy Lifestyle Modifications

Alcohol:

Many studies have proven that alcohol consumption increases the risk of breast cancer in women by about 7%-10% for each 10g (roughly one drink) of alcohol consumed per day on average [53, 54-56]. Women who have 2-3 alcoholic drinks per day have a 15% greater chance of getting breast cancer than those who do not drink. One of the mechanisms by which alcohol increases risk of breast cancer is by increasing estrogen and androgen levels [57]. Alcohol use has been more strongly related with increased risk for ER+ than ER- breast cancers [58, 59].

Body Weight: Women with heavy body weight have higher body mass index (BMI >25 kg/m²). After menopause they have greater risk of arriving breast cancer than women with normal weight. Being overweight increases one's chance of recurrence [90, 91]. So reduce the weight and maintain the BMI <21 kg/m² which lowers the risk of getting breast cancer.

Physical activity&Exercise: The women who get involve in regular physical activities or exercise have a 10%-25% lower risk of breast cancer compared to women who are inactive or non-exercise with stronger evidence for postmenopausal than premenopausal women [52, 48-50]. An American Cancer Society study describes that the breast cancer risk was 15% lower among women who reported walking 7-9 hours per week or exercising 4-7 hours per week compared to women who had not walked and exercised 3 or less than 3 hours per week [49]. The benefit may be due to the effects of physical activity on body mass, hormones, and energy balance [51].

Diet: *Brassica (Cruciferous) vegetables*

Diet including cruciferous vegetables have the higher chances of reducing breast cancer. Cruciferous vegetables are belongs to brassica family which contain indole-3-carbinol, which helps in reduction of cell proliferation, increases apoptosis. Breast cancer risk may be reduced by 20-40% with 1-2 servings of cruciferous vegetables daily. [14, 15, 16]

Green Tea

Green tea is a polyphenol and natural aromatase inhibitor. Green tea ingestion of 3 cups or more per day in two studies reduced the risk of breast cancer.[17,18]

Calcium and Vitamin-D

The role of calcium in carcinogenesis derives from its involvement in regulating cell proliferation, differentiation, and apoptosis (26-28). The concentration of calcium is inversely proportional to the cell proliferation and induces differentiation of mammary cells in experimental studies (25, 29, and 30). In rodent models, high intake of calcium has been shown to suppress high-fat diet-induced epithelial hyper proliferation of the mammary gland and mammary tumorigenesis induced by 7, 12-dimethylbenz (a) anthracene (25). Vitamin-D compounds induces the apoptosis in breast cancer cells [27]. 1, 25(OH) 2D, a biologically active form of vitamin-D, expresses its activity mainly by binding to specific receptors [31].

Experimental studies have shown that 1, 25(OH) 2D regulates the cell proliferation and induces apoptosis in normal and malignant breast cancer cells [32-35].

Clinical practice points

Clinically breast cancer has different modes of treatments. Surgery, chemotherapy and hormone therapies, radiation are commonly used therapies to treat the breast cancer. In chemotherapy, anthracyclins like doxorubicin and paclitaxel are generally used compounds. In hormone therapy, tamoxifen and arimidex are the two compounds frequently used to treat the hormonal positive breast cancers. The above treatments including with radiation treatment are generally preferred at stage iii and stage iv levels of breast cancer. The above study signifies that prevention is key to reduce the burden of breast cancer. Regular exercise and physical activities, low alcohol intake, consumption of fruits and cruciferous vegetables in diet, maintaining BMI > 21 kg/m², avoid late night shift works, awareness of work place exposure to hazardous chemicals are some of the clinical points which might reduce the risk of breast cancer.

CONCLUSION

Breast cancer is a fast growing cancer in women in the world, the life expectancy of breast cancer patients decreases due to lack of awareness, improper treatment and not following the preventive steps. Increased awareness among women and improvement in diagnostic procedure, earlier detection of breast cancer may increase the long-term survival of patients. From this review article it is concluded that risk of breast cancer is reduced by following some preventive steps like doing regular exercises or yoga, physical activity, include brassica (cruciferous) vegetables and fruits in diet which contains many anti-oxidants, avoid alcohol intake, take green tea regularly and avoid smoking because the long term smoking also affect the risk of breast cancer. More research on the connection between workplace exposures and the risk of breast cancer is urgently needed, obtaining detailed occupational histories and tracking and understanding the impact of shift work is difficult to find. Workplace and governmental agencies should protect workers from occupational exposures to hazardous chemicals that adversely affect quality of life, shortens the life span of workers. Maintain higher levels of Calcium and vitamin-D which regulates cell proliferation, inhibits the growth of malignant breast cancer cells. In addition to use of chemotherapeutic and hormone therapeutic drugs, changing life style modifications and following preventive steps will reduce the risk of breast cancer.

References

1. Aguas F, Martins A, Gomes TP, de Sousa M, Silva DP; Portuguese Menopause Society and Portuguese Gynaecology Society (2005) Prophylaxis approach to A-symptomatic post-menopausal women: breast cancer. *Maturitas* 52: S23-31.
2. Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk -- where do we stand in 2005? *J Cell Mol Med* 9: 208-221.
3. Russell (2000) Bailey and Love's Short Practice of Surgery. In Chapter on breast cancer (23rd edn) Arnold, London.
4. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. *Nat Rev Cancer* 2: 101-112.
5. Weinberg OK, Marquez-Garban DC, Pietras RJ (2005) new approaches to reverse resistance to hormonal therapy in human breast cancer. *Drug Resist Updat* 8: 219-233.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer 2006.
7. Kamdar, B. B., Tergas, A. I., Mateen, F. J., Bhayani, N. H., & Oh, J. (2013). Night-shift work and risk of breast cancer: A systematic review and meta-analysis. *Breast Cancer Research and Treatment*, 138(1), 291–301. doi:10.1007/s10549-013-2433-1

8. Menegaux, F., Truong, T., Anger, A., Cordina-Duverger, E., Lamkarkach, F., Arveux, P., Guénel, P. (2013). Night work and breast cancer: A population-based case-control study in France (the CECILE study). *International Journal of Cancer*, 132(4), 924–931. doi:10.1002/ijc.27669
9. Megdal, S. P., Kroenke, C. H., Laden, F., Pukkala, E., & Schernhammer, E. S. (2005). Night work and breast cancer risk: A systematic review and meta-analysis. *European Journal of Cancer*, 41(13), 2023–2032. doi:10.1016/j.ejca.2005.05.010
10. Slack, R., Young, C., & Rushton, L. (2012). Occupational cancer in Britain. *British Journal of Cancer*, 107, S27–S32. doi:10.1038/bjc.2012.115
11. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. *N Engl J Med*. 2011;365(14):1304-14.
12. Greenberg ER, Barnes AB, Resseguie L, Barrett JA, Burnside S, Lanza LL, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. *N Engl J Med*. 1984;311(22):1393-8.
13. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2006;15(8):1509-14.
14. Brew CT, Aronchik I, Hsu JC, et al. Indole 3 carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. *Int J Cancer* 2006;118:857-868.
15. Ambrosone CB, McCann SE, Freudenheim JL, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. *J Nutr* 2004;134:1134-1138.
16. Fowke JH, Chung FL, Jin G, et al. Urinary isothiocyanate levels, brassica and human breast cancer. *Cancer Res* 2003;63:3980-3986.
17. Huang X, Holman CD. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. *International Journal of Cancer* 2009;124:1404-1408.
18. Ogunleye AA, Xue F, Michels KB. Green tea consumption and breast cancer risk or recurrence: a meta-analysis. *Breast Cancer Research and Treatment* 2010;119:477-484.
19. kamdar, B. B., Tergas, A. I., Mateen, F. J., Bhayani, N. H., & Oh, J. (2013). Night-shift work and risk of breast cancer: A systematic review and meta-analysis. *Breast Cancer Research and Treatment*, 138(1), 291–301. doi:10.1007/s10549-013-2433-1
20. Menegaux, F., Truong, T., Anger, A., Cordina-Duverger, E., Lamkarkach, F., Arveux, P., Guénel, P. (2013). Night work and breast cancer: A population-based case-control study in France (the CECILE study). *International Journal of Cancer*, 132(4), 924–931. doi:10.1002/ijc.27669
21. Megdal, S. P., Kroenke, C. H., Laden, F., Pukkala, E., & Schernhammer, E. S. (2005). Night work and breast cancer risk: A systematic review and meta-analysis. *European Journal of Cancer*, 41(13), 2023–2032. doi:10.1016/j.ejca.2005.05.010
22. Slack, R., Young, C., & Rushton, L. (2012). Occupational cancer in Britain. *British Journal of Cancer*, 107, S27–S32. doi:10.1038/bjc.2012.115
23. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a metaanalysis. *Int J Cancer* 2007;121:856-62.
24. 22. Chaplan F. Differential Effects of Reproductive Factors on the risk of pre and post-menopausal breast cancer: Results from a large cohort French women. *British J of Cancers*. 2002; 86:723-7.
25. Xue L, Lipkin M, Newmark H, Wang J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. *J Natl Cancer Inst* 1999;91:176-81.
26. Whitfield JF, Boynton AL, MacManus JP, Sikorska M, Tsang BK. The regulation of cell proliferation by calcium and cyclic AMP. *Mol Cell Biochem* 1979;27:155 – 79.
27. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. *J BiolChem* 2002;277: 30738 – 45.

28. Sergeev IN. Calcium as a mediator of 1,25-dihydroxyvitamin D₃-induced apoptosis. *J Steroid BiochemMolBiol* 2004;89 – 90:419 – 25.
29. McGrath CM, Soule HD. Calcium regulation of normal human mammary epithelial cell growth in culture. *In Vitro* 1984;20:652 – 62.
30. Russo J, Russo IH. The pathway of neoplastic transformation of human breast epithelial cells. *Radiat Res* 2001;155:151 – 4.
31. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994;63:451 – 86.
32. Welsh J. Vitamin D and breast cancer: insights from animal models. *Am J ClinNutr* 2004; 80:1721 – 4S.
33. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 α ,25- DihydroxyvitaminD (3) inhibits angiogenesis in vitro and in vivo. *Circ Res*2000;87:214 – 20
34. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. *Lancet* 1989;1:188 – 91.
35. Saez S, Falette N, Guillot C, Meggouh F, Lefebvre MF, Crepin M. William L. McGuire Memorial Symposium. 1,25(OH) 2D₃ modulation of mammary tumor cell growth in vitro and in vivo. *Breast Cancer Res Treat* 1993;27: 69 – 81.
36. Ferley J et al. GLOBACAN2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. 2014;
37. American cancer society, Cancer Treatment and Survivorship Facts & Figures 2014-2015,2014, American Cancer Society, Atlanta.
38. Ferlay J BF, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. 2001.
39. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010 [cited 2011 October 25, 2011]; Available from: <http://globocan.iarc.fr>
40. Pasqualini JR, Schatz B, Varin C, et al. Recent data on estrogensulfatases and sulfotransferases activities in human breast cancer. *J Steroid BiochemMolBiol* 1992; 41:323-329.
41. Dumestrescu RG, Cotarla I. Understanding breast cancer risk – where do we stand in 2005? *J Cell Mol Med* 2005;9:208-221.
42. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 2001;358:1389-1399.
43. Zhang SM, Lee I, Manson JA, et al. Alcohol Consumption and Breast Cancer risk in the Women's health study. *Am J of Epidemiol.* 2007;165:667 - 76.
44. Key J, Hodgson S, Omar RZ, et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes Control.* 2006;17:759 – 70
45. Takimoto CH, Calvo E: Principles of oncologic pharmacotherapyin: Pazdur KR, Wagman LD, Camphausen KA, Hoskins WJ (Eds) *Cancer Management: A Multidisciplinary Approach*, 11 ed. 2008.
46. Smith I, Chua S, Smith I, Chua S. Medical treatment of early breast cancer. III: chemotherapy. [Review] [0 refs]. *BMJ* 2006 Jan 21;332(7534):161-2.
47. Early Breast Cancer Trialists' Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet.* 2011;378: 1707-1716.
48. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC. Physical activity and risk of breast cancer among postmenopausal women. *Arch Intern Med.* 2010;170: 1758-1764.
49. Hildebrand JS, Gapstur SM, Campbell PT, Gaudet MM, Patel AV. Recreational physical activity and leisure-time sitting in relation to postmenopausal breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2013;22: 1906-1912.

50. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. *Breast Cancer Res Treat.* 2013;137: 869-882.
51. Neilson HK, Friedenreich CM, Brockton NT, Millikan RC. Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. *Cancer Epidemiol Biomarkers Prev.* 2009;18: 11-27.
52. World Cancer Research Fund/American Institute for Cancer Research. *Food, nutrition, physical activity, and the prevention of cancer: a global perspective.* Washington, DC: AICR, 2007.
53. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: a look at the evidence. *Women's Health (London, England).* 2015;11: 65-77.
54. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. *Br J Cancer.* 2002;87: 1234-1245.
55. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA.* 2011;306: 1884-1890.
56. Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. *J Natl Cancer Inst.* 2009;101: 296-305.
57. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. *JAMA.* 2001;286: 2143-2151
58. Li CI, Chlebowski RT, Freiberg M, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. *J Natl Cancer Inst.* 2010;102: 1422-1431.
59. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies. *Int J Cancer.* 2008;122: 1832-1841.
60. Early Breast Cancer Trialists' Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet.* 2011;378: 1707-1716.
61. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med.* 2002;347: 1233-1241.
62. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med.* 2002;347: 1227-1232.
63. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. *Lancet Oncol.* 2012;13: 412-419.
64. Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet.* 2011; 378: 771-784.
65. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet.* 2012.
66. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet.* 2013;381: 805-816.

67. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. *J ClinOncol*. 2014;32: 2255-2269.
68. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. *Ann SurgOncol*. 2009;16: 2682-2690.
69. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of locoregional therapy among young women with breast cancer. *Breast Cancer Res Treat*. 2012;135: 893-906.
70. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. *Annu Rev Genomics Hum Genet*. 2008;9: 321-345.
71. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *ProcNatlAcadSciU S A*. 2014;111: 14205-14210.
72. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet*. 2003;72: 1117-1130.
73. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J ClinOncol*. 2007;25: 1329-1333.
74. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst*. 2013;105: 812-822.
75. World Cancer Research Fund/American Institute for Cancer Research. *Food, nutrition, physical activity, and the prevention of cancer: a global perspective*. Washington, DC: AICR, 2007.
76. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. *Oncologist*. 2011;16: 726-729.
77. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). *New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973- 2000*. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.
78. Chen Y, Semenciw R, Kliwer E, Shi Y, Mao Y. Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada. *Breast Cancer Res Treat* 2001;67:35-40.
79. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer.
 - a. *Cancer Epidemiol Biomarkers Prev* 1999;8:855-61.
80. Willett W, Rockhill B, Hankinson S, Hunter D, Colditz G. Chapter 15: Epidemiology and Nongenetic Causes of Breast Cancer. In: Harris J, ed. *Diseases of the Breast*. Philadelphia: Lippincott Williams and Wilkins, 2004
81. Colditz G, Baer H, Tamimi R. *Epidemiology of Breast Cancer*. New York: Oxford University Press, 2005
82. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. *Epidemiol Rev* 1993;15:36-47
83. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. *J Mammary Gland BiolNeoplasia* 2002;7:3-15.
84. National Breast Cancer Centre*. *The clinical management of ductal carcinoma in situ, lobular carcinoma in situ and atypical hyperplasia of the breast*. Camperdown (Australia): National Breast Cancer Centre*; 2003.
85. Hurley S, Hart S, Susil B. *Prevalence, screening and management of atypical hyperplasia and lobular carcinoma in situ*. Woolloomooloo (NSW): NHMRC National Breast Cancer Centre*, 1997.
86. Khuder SA, Mutgi AB, Nugent S. Smoking and breast cancer: a meta-analysis. *Rev Environ Health* 2001;16:253-61.
87. Morabia A. Smoking (active and passive) and breast cancer: epidemiologic evidence up to June 2001. *Environ Mol Mutagen* 2002;39:89-95.
88. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. *Cancer Epidemiol Biomarkers Prev* 2002;11:953-71.

89. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. *Breast Cancer Res Treat* 2006;100:293-9.
90. Friedenreich CM. Review of anthropometric factors and breast cancer risk. *Eur J Cancer Prev* 2001;10:15-32.
91. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. *Am J Epidemiol* 2000;152:514-27.
92. Abeloff MD AJ, Lichter AS, et al, eds., editor. *Clinical Oncology*. 4th ed. Philadelphia, PA: Elsevier; 2008.
93. American Cancer Society, Inc., Surveillance Research, 2015.
94. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet*. 2001;358: 1389-1399.
95. Howlander N, Noone AM, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2012*. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Bethesda, MD: National Cancer Institute, 2015.
96. Copeland G, Lake A, Firth R, et al. *Cancer in North America: 2008- 2012. Volume One: Combined Cancer Incidence for the United States, Canada and North America*. Springfield, IL: North American Association of Central Cancer Registries, Inc, June 2015.
97. Boyd NF, Martin LJ, Rommens JM, et al. Mammographic density: a heritable risk factor for breast cancer. *Methods Mol Biol*. 2009;472: 343- 360.
98. Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. *Am J Epidemiol*. 2011;174: 909-918.
99. Santen RJ. *Benign breast disease in women*. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext. South Dartmouth, MA: MDTText.com, Inc, 2014.
100. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. *Br J Cancer* 2002;87:876-82.
101. Willett W, Rockhill B, Hankinson S, Hunter D, Colditz G. Chapter 15: Epidemiology and Nongenetic Causes of Breast Cancer. In: Harris J, ed. *Diseases of the Breast*. Philadelphia: Lippincott Williams and Wilkins, 2004.
102. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet* 1997; 350:1047-59.